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Mistaken Guidelines for Thrombolytic Therapy of Acute Myocardial 
Infarction in the Elderly 
SOL SHERRY, MD, FACC, VICTOR J. MARDER, MD* 
Philadelphia, Pennsylvania and Rochester, New York 
In the recent "ACC/AHA Task Force Report on Guidelines 
for the Early Management of Patients with Acute Myocar-
dial Infarction" 0), the section on "Thrombolytic Therapy 
in Older Age Patients" misinterprets the data from the 
Second International Study of Infarct Survival (ISIS-2) (2) 
and Gruppo Italiano per 10 Studio della Streptochinasi 
nell'Infarto Miocardico (GISSI) (3), the only large, placebo-
controlled trials of streptokinase with no age exclusion. The 
Guidelines state: 
ISIS-2 reported a 16% reduction in the 5 week vascular 
mortality rate (18.2% versus 21.6%) in the streptokinase 
group >70 years of age at entry, a 26% reduction (10.6% 
versus 14.4%) in the streptokinase group in those 60 to 69 
years and a 28% reduction (4.2% versus 5.8%) in the 
streptokinase group in <60 years. The GISSI trial noted a 
13% reduction in mortality at 3 weeks in those >75 years, 
and 8% reduction in those 65 to 75 years, and a 26% 
reduction in those :s65 years. 
On this basis, the "Guidelines" conclude that there is an 
"attenuation of streptokinase effect with increasing age" 
and that "the administration of thrombolytic therapy to 
older patients should be judicious." 
While the use of thrombolytic therapy in older, as well as 
younger, patients always should be judicious, the judgment 
of the Guidelines is flawed in two respects. First, the 
conclusions are based only on the percent reduction in 
mortality rate, rather than on the more meaningful analysis 
of lives saved per 1,000 patients treated. Second, the data 
that were cited were obtained using streptokinase without 
aspirin. The results obtained by using a combination of 
streptokinase with aspirin are significantly better and the 
standard of care dictates that this or other active adjunct 
agents be combined with streptokinase or other fibrinolytic 
agents. 
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Table I tabulates the data from the trials reported in the 
"Guidelines" (percent mortality reduction) but, in addition, 
includes a calculation of the lives saved per 1,000 patients 
treated. In addition, it indicates the results in ISIS-2 using 
the combination of streptokinase with aspirin. 
In fact, the data indicate results opposite from those cited 
in the "Guidelines." In ISIS-2 the number of lives saved per 
1,000 patients treated with streptokinase alone was 16 for 
patients <60 years of age, 38 for those 60 to 69 years and 34 
for those> 70 years. In GISSI, the values are 20 for patients 
<65 years of age, 15 for the 65 to 75 year age group and 42 
for those> 75 years. Both studies show a superior effect in 
the >70 or >75 year groups than in the <60 or <65 year 
groups. 
Even more important and impressive are the results using 
streptokinase plus aspirin, which show 25 lives saved per 
1,000 patients <60 years old, 70 lives for the 60 to 69 year old 
group and 80 lives for the >70 year old group. These data 
clearly indicate an even more striking disparity, with the 
elderly (>70 years old) benefiting to a much greater degree 
with added aspirin than the patients <60 years old. 
Thus, the data from the GISSI and ISIS-2 trials do not 
support the contention made in the Guidelines of an attenu-
ation of effect by streptokinase in the elderly: rather, the 
reverse is true. Of course, one should always be judicious 
about bleeding risks in patient selection, young or old, but 
the overall benefit in lives saved is the more important 
consideration and this is achieved in the elderly. 
Considering the progressive increase in life span, the 
number of people in the >70 year age group will grow. Since 
acute myocardial infarction represents a major problem for 
these individuals, the "Guidelines" as currently stated mis-
represent the facts to their detriment. We recommend that 
an addendum to the "Guidelines" be published so as to 
correct this serious mistake. 
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Table 1. Mortality in Relation to Age in the ISIS-2 (2) and GISSI (3) Trials (Streptokinase or Streptokinase + Aspirin Versus Placebo) 
PI. Age 
Mortality Rate (%) Mortality Reduction With SK 
(yr) SK 
ISIS-2 <60 4.2 
(SK alone) 60-69 10.6 
>70 18.2 
GISSI <65 5.7 
(SK alone) 65-75 16.6 
>75 28.9 
ISIS-2 <60 3.7 
(SK plus aspirin) 60-69 9.1 
>70 15.8 
Pt. = patient; SK = streptokinase. 
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among 17,187 cases of suspected acute myocardial infarction: ISIS-2. 
Lancet 1988;2:525-30. 
3. Gruppo Italiano per 10 Studio della Streptochinasi nell'Infarto Miocardico 
(GISSl). Effectiveness of intravenous thrombolytic treatment in acute 
myocardial infarction. Lancet 1986;1:397-402. 
RESPONSE 
ROLF M. GUNNAR, MD, F ACC, Chairman, 
ACC/AHA Subcommittee to Develop 
Guidelines for the Early Management of 
Patients with Acute Myocardial Infarction (For 
the Subcommittee) 
We agree that the use of thrombolytic therapy in all subjects, 
including those over 75 years, should be judicious. Table VI 
from the February 1986 GISSI publication reveals differences 
in subjects over 65 and those over 75 that are not statistically 
significant. The data from ISIS-2 in those over 70 are statisti-
cally significant with and without aspirin. Thus, the observed 
differences in GISSI in those over 65 or 75 could have easily 
arisen by chance, and the observed differences in ISIS-2 in the 
over 70 group are unlikely to have arisen by chance. There 
were 2,886 patients between 65 and 75 randomized in GISSI 
and 3,411 randomized in ISIS-2 over 70. 
The Subcommittee believes that physicians should be 
judicious in selection of older patients for thrombolytic 
therapy since the two trials are not congruent in magnitude 
and statistical significance of observed differences. How-
ever, they are congruent in the direction of differences. A 
recent report (Anderson JL et al., Circulation 1990, Suppl 
111:111-431) reaffirms the caution needed in thrombolysis in 
patients over 75. 
Drs. Sherry and Marder are correct that absolute benefit 
Placebo % Lives Savedll,OOO 
5.8 28 16 
14.4 26 38 
21.6 16 34 
7.7 26 20 
18.1 8 15 
33.1 13 42 
6.2 40 25 
16.1 43 70 
23.8 34 80 
appears to increase with increased age, but so also does the 
burden of chronic illness and probably the risk associated 
with thrombolytic therapy. Thus, the selection of older 
patients with myocardial infarction for thrombolytic therapy 
should be done cautiously. The guidelines do give permis-
sive recommendation for thrombolysis in patients between 
70 and 75 years (class IIa) and patients over 75 (class lIb) 
rather than the firm recommendation of class I. The Sub-
committee continues to feel this recommendation appropri-
ate and perhaps Drs. Sherry and Marder have misinterpreted 
the grading of recommendations used in these guidelines. 
REBUTTAL TO SUBCOMMITTEE 
RESPONSE 
Dr. Gunnar on behalf of the Subcommittee implies that we 
are responsible for misinterpreting their report. However, 
their response does not adequately address the issue we 
raised. The Subcommittee report stated that there is an 
attenuation of the effect of thrombolytic therapy in the older 
age group based on an analysis of the GISSI 2 and ISIS 3 
data. Proper analysis of these data, as we pointed out, shows 
that there is no attenuation of mortality reduction in the aged 
based on the GISSI 2 and ISIS 3 data and, if anything, there 
is a strong trend toward a greater mortality reduction in this 
group. It is surprising that the Committee continues to beg 
the question of the use of thrombolytic therapy in the aged 
rather than simply correcting their error. Regardless of the 
presence of chronic illness and the usual cautions associated 
with thrombolytic therapy, patients should not be denied the 
mortality benefits of thrombolytic therapy because of age. 
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